[Isotretinoin in local treatment of acne and rosacea and animal experiment studies on isotretinoin and arotinoid].
Fifteen patients with acne and 4 with rosacea were treated topically with 0.2% isotretinoin cream twice a day for 16 weeks. Inflammatory lesions responded better (30 +/- 22 versus 15 +/- 12) than non-inflammatory lesions (23 +/- 44 versus 17 +/- 24). Neither the "causal level" (123 +/- 85 versus 130 +/- 66 micrograms/cm2 nor the "replacement sum" (70 +/- 29 versus 77 +/- 30 micrograms/cm2) were changed (lipometer assay). In 150 adult male Syrian hamsters 1-2 drops of isotretinoin in concentrations varying from 0.3% to 0.001% and arotinoid ranging in concentration from 0.3% to 0.00001% in acetone were applied to the left ventral ear or the left flank organ twice a day (5/7 days) for 21 days. In higher concentrations there was a significant reduction in sebaceous gland size. Arotinoid, however, is extremely toxic. Even in concentrations as low as 0.00001% the animals showed severe side-effects within the 1st week.
D000152:Acne Vulgaris / Q000188:drug therapy*; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000818:Animals; D001565:Benzoates / Q000627:therapeutic use*; D006224:Cricetinae; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015474:Isotretinoin; D008297:Male; D008647:Mesocricetus; D012176:Retinoids; D012393:Rosacea / Q000188:drug therapy*; D012627:Sebaceous Glands / Q000187:drug effects; D014212:Tretinoin / Q000627:therapeutic use*
D001565:Benzoates; D012176:Retinoids; D014212:Tretinoin; C034814:ethyl-p-((E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-1-propenyl)benzoic acid; D015474:Isotretinoin
Isotretinoin zur örtlichen Behandlung von Akne und Rosazea sowie tierexperimentelle Untersuchungen mit Isotretinoin und Arotinoid.